Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | GRM5 | P41594 | 1/20 | 0.67 |
| ▸ | TLR4 | O00206 | 1/20 | 0.58 |
| ▸ | TLR2 | O60603 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | TOP1 | P11387 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
| ▸ | PRKCA | P17252 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496950 | 1.00 | NPC1 (0.67) | NPC1RAB9AMAPTGRM5TLR4 | |
| SCHEMBL29496951 | 1.00 | NPC1 (0.67) | NPC1RAB9AMAPTGRM5TLR4 | |
| SCHEMBL8755737 | 0.86 | NPC1 (0.63) | NPC1RAB9AMAPTGRM5BCHE | |
| SCHEMBL28427262 | 0.86 | TLR4 (0.55) | NPC1RAB9AMAPTGRM5TLR4 | |
| SCHEMBL2644131 | 0.82 | NPC1 (0.55) | NPC1RAB9AMAPTBCHEACHE | |
| SCHEMBL4185953 | 0.81 | NPC1 (0.67) | NPC1RAB9AMAPTGRM5BCHE | |
| SCHEMBL2455727 | 0.81 | RAB9A (1.00) | NPC1RAB9AMAPTGRM5ALDH1A1 | |
| SCHEMBL2615553 | 0.81 | NPC1 (0.57) | NPC1RAB9AMAPTGRM5TLR4 | |
| SCHEMBL30461135 | 0.81 | RAB9A (0.69) | NPC1RAB9AMAPTBCHEACHE | |
| SCHEMBL30461136 | 0.81 | RAB9A (0.69) | NPC1RAB9AMAPTBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998007720-A1 | SUBSTITUTED 2-ARYLPYRIDINE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | claimed |
| EP-4638441-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-116283668-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2023-06-23 | — | — | CN | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3621951-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | Research Triangle Institute (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| CN-110621656-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2019-12-27 | — | — | CN | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996033192-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996033191-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996033194-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| WO-1994029277-A1 | AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-22 | — | — | WO | disclosed |
| US-5068337-A | Dihydrodicarboxypyridine as anticoagulants | JOHN WYETH & BROTHER LIMITED (GB) | 1991-11-26 | — | — | US | disclosed |
| EP-0387070-A2 | N-Containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4414213-A | CARDIOVASCULAR DISORDERS | MEAD JOHNSON & COMPANY (US) | 1983-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | NPC1 1047/4885RAB9A 857/4885MAPT 2523/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | NPC1 1047/4885RAB9A 857/4885MAPT 2523/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | NPC1 1047/4885RAB9A 857/4885MAPT 2523/4885 |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | NPC1 1047/4885RAB9A 857/4885MAPT 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.